Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells.

Rolle F, Bincoletto V, Gazzano E, Rolando B, Lollo G, Stella B, Riganti C, Arpicco S.

Int J Pharm. 2020 Mar 3;580:119191. doi: 10.1016/j.ijpharm.2020.119191. [Epub ahead of print]

PMID:
32142738
2.

Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.

Dallavalle S, Dobričić V, Lazzarato L, Gazzano E, Machuqueiro M, Pajeva I, Tsakovska I, Zidar N, Fruttero R.

Drug Resist Updat. 2020 Feb 7;50:100682. doi: 10.1016/j.drup.2020.100682. [Epub ahead of print] Review.

PMID:
32087558
3.

Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells.

Fathy Abd-Ellatef GE, Gazzano E, Chirio D, Hamed AR, Belisario DC, Zuddas C, Peira E, Rolando B, Kopecka J, Assem Said Marie M, Sapino S, Ramadan Fahmy S, Gallarate M, Abdel-Hamid AZ, Riganti C.

Pharmaceutics. 2020 Jan 24;12(2). pii: E96. doi: 10.3390/pharmaceutics12020096.

4.

Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets.

Kopecka J, Trouillas P, Gašparović AČ, Gazzano E, Assaraf YG, Riganti C.

Drug Resist Updat. 2020 Mar;49:100670. doi: 10.1016/j.drup.2019.100670. Epub 2019 Nov 29. Review.

PMID:
31846838
5.

Combination of PDT and NOPDT with a Tailored BODIPY Derivative.

Lazzarato L, Gazzano E, Blangetti M, Fraix A, Sodano F, Picone GM, Fruttero R, Gasco A, Riganti C, Sortino S.

Antioxidants (Basel). 2019 Nov 7;8(11). pii: E531. doi: 10.3390/antiox8110531.

6.

Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers.

Teodori E, Contino M, Riganti C, Bartolucci G, Braconi L, Manetti D, Romanelli MN, Trezza A, Athanasios A, Spiga O, Perrone MG, Giampietro R, Gazzano E, Salerno M, Colabufo NA, Dei S.

Eur J Med Chem. 2019 Nov 15;182:111655. doi: 10.1016/j.ejmech.2019.111655. Epub 2019 Aug 30.

PMID:
31494468
7.

Paracetamol-Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug.

Sodano F, Lazzarato L, Rolando B, Spyrakis F, De Caro C, Magliocca S, Marabello D, Chegaev K, Gazzano E, Riganti C, Calignano A, Russo R, Rimoli MG.

Mol Pharm. 2019 Oct 7;16(10):4181-4189. doi: 10.1021/acs.molpharmaceut.9b00508. Epub 2019 Sep 12.

PMID:
31465230
8.

Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells.

Salaroglio IC, Abate C, Rolando B, Battaglia L, Gazzano E, Colombino E, Costamagna C, Annovazzi L, Mellai M, Berardi F, Capucchio MT, Schiffer D, Riganti C.

Mol Pharm. 2019 Aug 5;16(8):3361-3373. doi: 10.1021/acs.molpharmaceut.9b00018. Epub 2019 Jul 2.

PMID:
31265310
9.

"Three-Bullets" Loaded Mesoporous Silica Nanoparticles for Combined Photo/Chemotherapy.

Tessaro AL, Fraix A, Pedrozo da Silva AC, Gazzano E, Riganti C, Sortino S.

Nanomaterials (Basel). 2019 May 31;9(6). pii: E823. doi: 10.3390/nano9060823.

10.

ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer.

Salaroglio IC, Mungo E, Gazzano E, Kopecka J, Riganti C.

Int J Mol Sci. 2019 May 21;20(10). pii: E2505. doi: 10.3390/ijms20102505. Review.

11.

Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?

Kopecka J, Gazzano E, Castella B, Salaroglio IC, Mungo E, Massaia M, Riganti C.

Semin Cell Dev Biol. 2020 Feb;98:80-89. doi: 10.1016/j.semcdb.2019.05.008. Epub 2019 May 18. Review.

PMID:
31100351
12.

Fluorescent Nitric Oxide Photodonors Based on BODIPY and Rhodamine Antennae.

Parisi C, Failla M, Fraix A, Rolando B, Gianquinto E, Spyrakis F, Gazzano E, Riganti C, Lazzarato L, Fruttero R, Gasco A, Sortino S.

Chemistry. 2019 Aug 22;25(47):11080-11084. doi: 10.1002/chem.201902062. Epub 2019 Jul 4.

PMID:
31074543
13.

Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.

Gazzano E, Buondonno I, Marengo A, Rolando B, Chegaev K, Kopecka J, Saponara S, Sorge M, Hattinger CM, Gasco A, Fruttero R, Brancaccio M, Serra M, Stella B, Fattal E, Arpicco S, Riganti C.

Cancer Lett. 2019 Aug 1;456:29-39. doi: 10.1016/j.canlet.2019.04.029. Epub 2019 Apr 29.

14.

Correction to "Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance".

Chegaev K, Fraix A, Gazzano E, Abd-Ellatef GEF, Blangetti M, Rolando B, Conoci S, Riganti C, Fruttero R, Gasco A, Sortino S.

ACS Med Chem Lett. 2019 Feb 28;10(3):393. doi: 10.1021/acsmedchemlett.9b00048. eCollection 2019 Mar 14.

15.

Pro- and anti-oxidant properties of near-infrared (NIR) light responsive carbon nanoparticles.

Kokalari I, Gassino R, Giovannozzi AM, Croin L, Gazzano E, Bergamaschi E, Rossi AM, Perrone G, Riganti C, Ponti J, Fenoglio I.

Free Radic Biol Med. 2019 Apr;134:165-176. doi: 10.1016/j.freeradbiomed.2019.01.013. Epub 2019 Jan 11.

PMID:
30639569
16.
17.

Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.

Salaroglio IC, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd-Elrahman GEFA, Massaia M, Donadelli M, Rubinstein M, Riganti C, Kopecka J.

J Exp Clin Cancer Res. 2018 Nov 27;37(1):286. doi: 10.1186/s13046-018-0967-0.

18.

Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma.

Buondonno I, Gazzano E, Tavanti E, Chegaev K, Kopecka J, Fanelli M, Rolando B, Fruttero R, Gasco A, Hattinger C, Serra M, Riganti C.

Cell Mol Life Sci. 2019 Feb;76(3):609-625. doi: 10.1007/s00018-018-2967-9. Epub 2018 Nov 14.

PMID:
30430199
19.

Mitochondrial Delivery of Phenol Substructure Triggers Mitochondrial Depolarization and Apoptosis of Cancer Cells.

Gazzano E, Lazzarato L, Rolando B, Kopecka J, Guglielmo S, Costamagna C, Chegaev K, Riganti C.

Front Pharmacol. 2018 Jun 4;9:580. doi: 10.3389/fphar.2018.00580. eCollection 2018.

20.

Aceclofenac-Galactose Conjugate: Design, Synthesis, Characterization, and Pharmacological and Toxicological Evaluations.

Magliocca S, De Caro C, Lazzarato L, Russo R, Rolando B, Chegaev K, Marini E, Nieddu M, Burrai L, Boatto G, Cristiano C, Marabello D, Gazzano E, Riganti C, Sodano F, Rimoli MG.

Mol Pharm. 2018 Aug 6;15(8):3101-3110. doi: 10.1021/acs.molpharmaceut.8b00195. Epub 2018 Jun 27.

PMID:
29912563

Supplemental Content

Loading ...
Support Center